Premature Birth clinical trials at UCLA
6 in progress, 3 open to eligible people
Bevacizumab Treatment For Type 1 ROP
open to eligible people ages up to 6 months
Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these severe cases. Also unknown is the timing and extent of peripheral retinal vascularization after low-dose bevacizumab compared with the standard dose. The current study will evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I.
Los Angeles, California and other locations
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
open to all eligible people
A comprehensive analysis of the impact of exogenous enteral DHA and ARA supplementation on lipid metabolism including the production of downstream derived mediators and how this impacts important biological pathways such as metabolism, inflammation, and organogenic factors.
Los Angeles, California and other locations
Follow-up Visit of High Risk Infants
open to eligible people ages 18 months to 26 months
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment.
Los Angeles, California and other locations
IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study
Sorry, in progress, not accepting new patients
IBP-9414 will be evaluated in preterm infants with a birth weight of 500-1500g, compared to placebo with regards to efficacy and safety in the prevention of necrotizing enterocolitis.
Los Angeles, California and other locations
Clinical Efficacy and Safety Study of OHB-607 in Preventing Chronic Lung Disease in Extremely Premature Infants
Sorry, in progress, not accepting new patients
The purpose of this study is to determine if an investigational drug can reduce the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Los Angeles, California and other locations
Hydrocortisone for BPD
Sorry, in progress, not accepting new patients
The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life. Infants will be randomized to receive hydrocortisone or placebo. This study will determine if hydrocortisone improves infants'survival without moderate or severe BPD and will be associated with improvement in survival without moderate or severe neurodevelopmental impairment at 22 - 26 months corrected age.
Los Angeles, California and other locations
Our lead scientists for Premature Birth research studies include Stacy L Pineles, MD Meena Garg Kara Calkins, MD.
Last updated: